Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PHAS

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

PhaseBio Pharmaceuticals logo

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
9.65 million shs
Average Volume
848,888 shs
Market Capitalization
$3.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PHAS Stock News Headlines

MedPharm appoints Bill Humphries as new CEO
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ)
Alcami Announces CEO Transition
See More Headlines

PHAS Stock Analysis - Frequently Asked Questions

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) posted its earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.07. The business had revenue of $0.34 million for the quarter, compared to the consensus estimate of $2.67 million.

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseBio Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM), VBI Vaccines (VBIV), Oncobiologics (OTLK), Viking Therapeutics (VKTX) and Anavex Life Sciences (AVXL).

Company Calendar

Last Earnings
11/10/2021
Today
7/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PHAS
CIK
1169245
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$131.07 million
Net Margins
-12,572.13%
Pretax Margin
-12,572.13%
Return on Equity
N/A
Return on Assets
-174.38%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.47
Quick Ratio
0.47

Sales & Book Value

Annual Sales
$818 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.93) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
49,858,000
Free Float
44,922,000
Market Cap
$3.50 million
Optionable
Not Optionable
Beta
2.57
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:PHAS) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners